Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Fineline Cube Apr 30, 2026
Company Deals

AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies

Fineline Cube Apr 17, 2024

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based...

Company Drug

Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech

Fineline Cube Apr 17, 2024

GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...

Company

J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact

Fineline Cube Apr 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter...

Policy / Regulatory

China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...

Policy / Regulatory

Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...

Drug Policy / Regulatory

China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...

Company Drug

AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial

Fineline Cube Apr 17, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...

Medical Device Policy / Regulatory

China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...

Company Deals

Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare

Fineline Cube Apr 17, 2024

Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced...

Company Drug

Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment

Fineline Cube Apr 17, 2024

Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...

Company Drug

China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment

Fineline Cube Apr 17, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...

Company

Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities

Fineline Cube Apr 16, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who...

Company Drug

Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor

Fineline Cube Apr 16, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers

Fineline Cube Apr 16, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...

Company Drug

Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial

Fineline Cube Apr 16, 2024

Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...

Company Drug

Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial

Fineline Cube Apr 16, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...

Policy / Regulatory

EU Set to Investigate China’s Medical Device Procurement Practices Amid Fairness Concerns

Fineline Cube Apr 16, 2024

The European Union (EU) is reportedly gearing up to launch an investigation into medical device...

Company Deals

Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System

Fineline Cube Apr 16, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership...

Company Deals Digital

Vazyme Partners with Yufang Medical to Boost Alzheimer’s Blood Test Sales Online

Fineline Cube Apr 16, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), based in China, has entered into a strategic partnership...

Company Drug

Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC

Fineline Cube Apr 15, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...

Posts pagination

1 … 367 368 369 … 659

Recent updates

  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
  • HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia
  • Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Company Medical Device

Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit

Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.